#Switzerland #ADC Therapeutics #ZYNLONTA #Lausanne #DLBCL

ADC Therapeutics Reports Fourth Quarter & Full Year 2025 Financial Results

ADC Therapeutics SA, a prominent player in the antibody drug conjugate (ADC) field, shared its financial outcomes for Q4 and the complete year of 2025. The company, trading under NYSE: ADCT, has demonstrated a growth trajectory and significant advancements within its operational framework.

Fourth Quarter Highlights

In the final quarter of 2025, ADC Therapeutics achieved a net product revenue of $22.3 million, representing an increase compared to the $16.4 million from Q4 2024. The company ended the year with a total revenue of $73.6 million, slightly higher than the $69.3 million reported in the previous year. CEO Ameet Mallik noted that these results reflect not only the stability of demand but also an increase in selling prices.

Research and Development Insights

Research and development costs for Q4 were approximately $18.2 million, surging downward from the $27.1 million spent in Q4 2024. This reduction is attributed to reduced spending on discontinued projects and the completion of essential studies related to their PSMA-targeting ADC. Total R&D expenses for the year came in at $104 million.

Strategic and Future Directions

ADC Therapeutics is eagerly anticipating the topline data from the LOTIS-5 Phase 3 trials which are expected in Q2 2026. This pivotal trial examines the efficacy of ZYNLONTA in combination with rituximab among patients with second-line or higher diffuse large B-cell lymphoma (DLBCL). Full data publication is anticipated by the end of 2026, potentially paving the way for a supplemental Biologics License Application (sBLA) in mid-2027 based on positive results.

Moreover, updates from the LOTIS-7 trial indicated a commendable 89.8% best overall response rate, showcasing the efficacy of ZYNLONTA when combined with glofitamab. Further results and updates are anticipated through medical meetings and publications scheduled for late 2026.

Financial Stability and Market Strategies

As of December 31, 2025, ADC Therapeutics reported cash and cash equivalents amounting to $261.3 million, showcasing enhanced financial stability which is expected to sustain operations through 2028. Recent amendments to the HealthCare Royalty financing agreement offer further strategic flexibility, potentially lowering the corporate liabilities during pivotal transitions.

The overall operational milestones such as these contribute to ADC Therapeutics’ poised strategy for future growth. With expectations set for compendia inclusions and regulatory approvals of their innovative therapies, the company is on a promising path to enhancing treatment options for patients worldwide.

Investor Engagement

ADC Therapeutics plans to host a conference call on March 10, 2026, to discuss the detailed financial results and updates on their operational strategies. Investors and interested parties are encouraged to tune in for insights directly from the company’s leadership on the future trajectory and operational integrity moving forward.

In conclusion, ADC Therapeutics’ report reflects a robust operational strategy and financial resilience that positions the company well within the competitive landscape of biotech firms dedicated to transforming patient care. Stakeholders will await the upcoming trial results and operational updates which could significantly affect the landscape of treatment for DLBCL and beyond.